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Reported herein, is the case of 21-year-old 
patient with repaired tetralogy of Fallot within her 
first year of life. Due to sick sinus syndrome and 
II grade atrioventricular block endocardial single-
chamber permanent pacemaker was inserted 
transvenously during her third year of life.
The patient was admitted in generally good 
condition aiming at pacemaker replacement. Right 
ventricle lead dysfunction was observed and thus, 
percutaneously removing and implantation of 
a new electrode was planned. Angio-computed 
tomography showed an obstruction of the superior 
vena cava. Pacemaker generator and lead were 
removed percutaneously but it was not possible to 
implant a new lead. The patient was managed with 
temporary transvenous pacing. The Heart Team 
qualified the patient for implantation of a leadless 
pacemaker (the MicraTM Transcatheter Pacing Sys-
tem, Medtronic, Minneapolis, MN, USA).
Implantation of the MicraTM was performed 
under general anesthesia.  Access via the right 
femoral vein was obtained with 23 Fr sheaths. 
MicraTM was fixed into upper part of the inter-
ventricular septum (Fig. 1). Implant parameters 
were optimal with 8.2 mV sensing, 650 Ohm 
electrode impedance and pacing threshold 0.5 V/ 
/0.24 ms. There were no complications. The time 
of fluoroscopy was 13 min, and exposition dose 
was 864 mGy. 
The patient was discharged receiving beta-
-blocker. The pacing threshold increased, reaching 
a maximum of 3.5 V at 0.24 ms during the first, 
and second month post-implantation. At 3-month 
follow-up pacing threshold decreased below 3.0 V/ 
/0.24 ms and was stabile until the 21-month follow-
up. Other parameters were stable during follow-
up. The stimulation percentage ranged from 1% 
to 12.8%.
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Figure 1. Location of the MicraTM device in fluoroscopy during the implantation procedure (A, B). Electrical parameters 
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